Asia
Executives from Israel-based companies express concern about future investment and other operational impacts, as the war rages on in Gaza with tragic loss of life amid political and economic uncertainties.
Social media campaigns may have been one factor that prompted Johnson & Johnson and Danaher to make a TB treatment and a test more accessible in low- and middle-income countries.
The companies will evaluate Moderna’s investigational Claudin18.2 mRNA cancer vaccine in combination with CARsgen’s Claudin18.2 CAR T cell candidate.
The biotech has acquired an exclusive global license for Shanghai-based DualityBio’s investigational antibody-drug conjugate for select solid tumors.
The company has signed a memorandum of understanding and land collaboration agreement to develop medicines exclusively for Chinese use.
As geopolitical tensions rise in the region, AstraZeneca is looking at potentially spinning off its China unit into its own independent business.
The deal with BlissBio is the latest in a cascade of multi-million- and billion-dollar acquisitions and collaborations centered on antibody-drug conjugates.
The past two decades were all about nucleic acid reading and writing. The next is about delivering DNA and RNA, Yogev Debbi, CEO of Mana.bio, told BioSpace in an interview.
Artificial intelligence and machine learning could change the face of cancer diagnostics. BioSpace spoke with the University of Waterloo, Gina Life and OncoHost to find out how.
AI/ML applications are being deployed at large pharmaceutical companies, but in order to truly maximize their potential, better infrastructure is needed. AION Labs believes it is answering that call.
PRESS RELEASES